For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaxis cancer drug doubles response rate to standard therapy in blood cancer pre clinical studies
- Nature Communications publishes peer-reviewed data from highly predictive pre clinical models using cells from mylodysplastic syndrome patients
- Best in class results from Combination of PXS-5505 and standard of care demonstrates a strong rationale for treatment of several blood cancers
Pharmaxis Ltd (ASX: PXS) will release its Quarterly Shareholder Update on the morning of 31 January 2023.
Investors and analysts are invited to participate in a virtual investor briefing by the Company’s chief executive officer Mr Gary Phillips at 11.30am AEDT on Tuesday 31 January 2023.
The event will consist of a short presentation of the Company’s progress over the past quarter and future plans followed by a Q&A session from attendees.
The event is free to attend, and investors should register in advance using the following registration link:
Upon registration, instructions for joining the session will be sent via email.
To ensure as many questions as possible can be responded to in the allotted time, Pharmaxis welcomes investors to pre-submit questions by emailing them to: email@example.comRead full media release - pdf
Pharmaxis Appoints Hashan De Silva as Director Adding Further Healthcare and Capital Market Expertise to The Board
Clinical stage drug developer Pharmaxis Ltd (ASX: PXS) is pleased to announce the appointment of healthcare investment professional Hashan De Silva to the Board as a non-executive director.
Mr De Silva is an experienced life sciences investment professional. He worked as associate healthcare analyst at Macquarie Group and lead healthcare analyst at CLSA Australia before joining Karst Peak Capital in February 2021 as head of healthcare research. Prior to moving into life science investment Mr De Silva worked at Eli Lilly in various roles focused on the commercialisation of new and existing pharmaceuticals.
Mr De Silva was educated at the University of New South Wales (Bachelor’s Degree in Medicine and Master’s Degree in Finance) and is a Chartered Financial Analyst.
Pharmaxis Chairman Malcolm McComas said, “We welcome Hashan to the Pharmaxis Board. He has been an enthusiastic supporter of the Company throughout his healthcare banking career including more recently as head of healthcare research at Karst Peak Capital where he conducted extensive diligence on our science which underpinned three separate investments in Pharmaxis. Hashan’s knowledge of the Australian and international healthcare capital markets brings relevant insight and experience to the Pharmaxis board.”
Mr De Silva said, “Pharmaxis has built a very impressive drug discovery and development capability unique from other ASX listed pharmaceutical companies. The clinical stage assets have generated exciting early data in diseases with high unmet need. I look forward to contributing to the commercialisation of these assets to create value for shareholders and deliver much needed new treatment options to patients.”Read full media release - pdf